Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.17 +2.1%	$2.97	$1.05 ▼ $3.97	$357.75M	1.92	757,165 shs	1.18 million shs
FULC Fulcrum Therapeutics	$6.88 +5.5%	$7.11	$2.32 ▼ $9.90	$372.15M	2.47	979,802 shs	362,286 shs
OTLK Oncobiologics	$2.68 +11.2%	$2.01	$0.87 ▼ $8.32	$119.04M	0.26	1.88 million shs	3.69 million shs
ZYBT Zhengye Biotechnology	$6.98 +4.2%	$6.48	$3.50 ▼ $14.30	$329.22M	N/A	139,516 shs	52,925 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+0.80%	-2.16%	+31.06%	+7.47%
FULC Fulcrum Therapeutics	0.00%	+0.88%	-12.02%	+6.83%	-27.88%
OTLK Oncobiologics	0.00%	+14.53%	+34.00%	+67.50%	-63.14%
ZYBT Zhengye Biotechnology	0.00%	-7.06%	+25.77%	-18.17%	+697,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.9707 of 5 stars	3.5	1.0	0.0	0.0	2.6	0.8	0.6
FULC Fulcrum Therapeutics	0.9437 of 5 stars	2.3	1.0	0.0	0.0	2.2	1.7	0.0
OTLK Oncobiologics	2.3198 of 5 stars	3.4	2.0	0.0	0.0	3.9	0.0	0.6
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	144.87% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.05% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	258.21% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OTLK, ZYBT, ADCT, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	OTLK Oncobiologics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	5.03	N/A	N/A	($1.77) per share	-1.79
FULC Fulcrum Therapeutics	$80M	4.65	N/A	N/A	$3.96 per share	1.74
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($0.84) per share	N/A
ZYBT Zhengye Biotechnology	$186.36M	1.77	$0.10 per share	67.74	$1.02 per share	6.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	11/12/2025 (Estimated)
OTLK Oncobiologics	-$75.37M	-$0.57	N/A	N/A	N/A	N/A	N/A	-332.30%	N/A
ZYBT Zhengye Biotechnology	$1.55M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OTLK, ZYBT, ADCT, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	OTLK Oncobiologics	-$0.42	-$0.44	-$0.02	-$0.55	$1.66 million	$1.51 million
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
FULC Fulcrum Therapeutics	N/A	24.42	24.42
OTLK Oncobiologics	N/A	0.67	0.57
ZYBT Zhengye Biotechnology	0.01	1.31	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
FULC Fulcrum Therapeutics	89.83%
OTLK Oncobiologics	11.20%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
FULC Fulcrum Therapeutics	7.00%
OTLK Oncobiologics	4.80%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
OTLK Oncobiologics	20	44.42 million	42.29 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

OTLK, ZYBT, ADCT, and FULC Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd trading resumes

August 22 at 9:45 AM | msn.com

Zhengye Biotechnology Holding Ltd trading halted, volatility trading pause

August 21 at 2:55 PM | msn.com

Zhengye Biotechnology (NASDAQ:ZYBT) Raised to Hold at Wall Street Zen

August 2, 2025 | marketbeat.com

ZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...

July 17, 2025 | wsj.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock News

July 3, 2025 | gurufocus.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

July 3, 2025 | prnewswire.com

ZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron's

July 2, 2025 | barrons.com

ZYBT - Zhengye Biotechnology Holding Ltd Chart - Morningstar

June 27, 2025 | morningstar.comM

Zhengye Biotechnology Holding Ltd

June 21, 2025 | morningstar.comM

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK, ZYBT, ADCT, and FULC Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.16 +0.07 (+2.10%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.20 +0.03 (+0.95%)

As of 08/22/2025 06:14 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Fulcrum Therapeutics NASDAQ:FULC

$6.88 +0.36 (+5.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.00 (+0.01%)

As of 08/22/2025 05:10 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Oncobiologics NASDAQ:OTLK

$2.68 +0.27 (+11.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.72 +0.03 (+1.31%)

As of 08/22/2025 07:59 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Zhengye Biotechnology NASDAQ:ZYBT

$6.98 +0.28 (+4.18%)

As of 08/22/2025 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time